Everything below concerns Ghrelin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-03. Numbers and descriptions here follow the published literature rather than marketing material.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
== History == In the 17th century, copper miners in Saxony, Germany, began to experience irritation caused by a "dark red ore". Since the substance, which would later be called nickel, led to many ailments, they believed it to be protected by "goblins", and called it "Goblin's Copper". Josef Jadassohn described the first case of metal contact dermatitis in 1895, to a mercury-based therapeutic cream, and confirmed the cause by epicutaneous patch testing. In the next century nickel began to be mass-produced for jewelry worldwide due to its cheap cost, resistance to corrosion and high supply. American Metal Market predicted in 2001 that concerns about the health effects of nickel and the use of nickel-free Nordic gold in the Euro would impact the nickel market, estimating 50,000 to 70,000 tonnes of nickel would be scrapped from obsolete coinage in 2002. A large comprehensive study of healthy US volunteers in 1979 found that 9% had been unknowingly sensitized to nickel. As of 2008, that number has tripled. Most importantly, nickel allergy among children is increasing, with an estimated 250,000 children sensitized to nickel. Published literature shows an exponential increase in reported nickel allergy cases. The North American Contact Dermatitis Group (NACDG) patch tested 5,085 adults, presenting with eczema-like symptoms, showing 19.5% had a positive reaction to nickel. Nickel allergy is also more prevalent in women (17.1%) than men (3%), possibly due to cultural norms related to jewelry and ear piercings and therefore increased exposure to nickel.
The on-call CT squadron is split into four troops, two of which are on immediate notice to move and are restricted to the Hereford-Credenhill area, whilst the other two conduct training and exercises across the UK, but are available for operational deployment should the need arise.
== Clinical significance == The GPx1 allele with five Ala repeats is significantly associated with breast cancer risk. Kocabasoglu, et al., sought to investigate connections between oxidative stress genes, including GPX1, and Panic Disorder, an anxiety disorder characterized by random and unexpected attacks of intense fear. Although the GPX1 Pro198Leu polymorphism, in general, did not significantly correlate with panic disorder risk, the study found a plausible association of the C allele of the GPX1 Pro198Leu polymorphism, found to be more frequent in the female cohort, with PD development. Ergen and colleagues analyzed gene expression of oxidative stress genes, specifically GPX1, in colorectal tumors in comparison to healthy colorectal tissues. ELISA was utilized to quantify GPX1 protein expression levels in both tissue types, highlighting a 2-fold decrease in tumor tissue (p<0.05). In esophageal cancer, Chen and colleagues found that vitamin D, a known suppressor of GPX1 expression via the NF-κB signaling pathway, could help to decrease the proliferative, migratory, and invasive capabilities of esophageal cancer cells. Unlike in colorectal cancer, GPX1 expression in esophageal cancer cells is thought to drive aggressive growth and metastasis, but Vitamin D-mediated decrease in GPX1 prevents such growth.
==== MeSH E05.318.740 – statistics ==== MeSH E05.318.740.100 – actuarial analysis MeSH E05.318.740.150 – analysis of variance MeSH E05.318.740.150.500 – multivariate analysis MeSH E05.318.740.200 – area under curve MeSH E05.318.740.250 – cluster analysis MeSH E05.318.740.250.675 – small-area analysis MeSH E05.318.740.250.700 – space-time clustering MeSH E05.318.740.275 – confidence intervals MeSH E05.318.740.300 – data interpretation, statistical MeSH E05.318.740.350 – discriminant analysis MeSH E05.318.740.400 – factor analysis, statistical MeSH E05.318.740.475 – matched-pair analysis MeSH E05.318.740.500 – models, statistical MeSH E05.318.740.500.475 – likelihood functions MeSH E05.318.740.500.500 – linear models MeSH E05.318.740.500.525 – logistic models MeSH E05.318.740.500.600 – models, economic MeSH E05.318.740.500.600.500 – models, econometric MeSH E05.318.740.500.625 – nomograms MeSH E05.318.740.500.700 – proportional hazards models MeSH E05.318.740.525 – monte carlo method MeSH E05.318.740.600 – probability MeSH E05.318.740.600.200 – Bayes' theorem MeSH E05.318.740.600.400 – likelihood functions MeSH E05.318.740.600.500 – markov chains MeSH E05.318.740.600.600 – odds ratio MeSH E05.318.740.600.700 – proportional hazards models MeSH E05.318.740.600.800 – risk MeSH E05.318.740.600.800.450 – logistic models MeSH E05.318.740.600.800.715 – risk assessment MeSH E05.318.740.600.800.725 – risk factors MeSH E05.318.740.600.900 – uncertainty MeSH E05.318.740.750 – regression analysis MeSH E05.318.740.750.400 – least-squares analysis MeSH E05.318.740.750.425 – linear models MeSH E05.318.740.750.450 – logistic models MeSH E05.318.740.750.725 – proportional hazards models MeSH E05.318.740.872 – sensitivity and specificity MeSH E05.318.740.994 – statistical distributions MeSH E05.318.740.994.250 – binomial distribution MeSH E05.318.740.994.300 – chi-square distribution MeSH E05.318.740.994.500 – normal distribution MeSH E05.318.740.994.750 – poisson distribution MeSH E05.318.740.995 – statistics, nonparametric MeSH E05.318.740.996 – stochastic processes MeSH E05.318.740.996.500 – markov chains MeSH E05.318.740.998 – survival analysis MeSH E05.318.740.998.300 – disease-free survival
A set of NRPS enzymes (peptide synthase VpsA, VpsB, and VpsC) are responsible for assembling the heptapeptide. (Figure 2). VpsA codes for modules 1, 2, and 3. VpsB codes for modules 4, 5, and 6, and VpsC codes for module 7. The vancomycin aglycone contains 4 D-amino acids, although the NRPSs only contain 3 epimerization domains. The origin of D-Leu at residue 1 is unknown. The three peptide syntheses are at the start of the region of the bacterial genome linked with antibiotic biosynthesis, and span 27 kb. β-hydroxytyrosine (β-HT) is synthesized before incorporation into the heptapeptide backbone. L-tyrosine is activated and loaded on the NRPS VpsD, hydroxylated by OxyD, and released by the thioesterase Vhp. The timing of the chlorination by halogenase VhaA during biosynthesis is undetermined, but is proposed to occur before the complete assembly of the heptapeptide. After the linear heptapeptide molecule is synthesized, vancomycin must undergo further modifications, such as oxidative cross-linking and glycosylation, in trans by distinct enzymes, referred to as tailoring enzymes, to become biologically active (Figure 3). To convert the linear heptapeptide to cross-linked, glycosylated vancomycin, six enzymes are required. The enzymes OxyA, OxyB, OxyC, and OxyD are cytochrome P450 enzymes. OxyB catalyzes oxidative cross-linking between residues 4 and 6, OxyA between residues 2 and 4, and OxyC between residues 5 and 7. This cross-linking occurs while the heptapeptide is covalently bound to the PCP domain of the 7th NRPS module.
Sources: en.wikipedia.org
Hybrids are offspring resulting from the breeding of two genetically distinct individuals, which usually will result in a high degree of heterozygosity, though hybrid and heterozygous are not synonymous. The deliberate or accidental hybridizing of two or more species of closely related animals through captive breeding is a human activity which has been in existence for millennia and has grown for economic purposes. Hybrids between different subspecies within a species (such as between the Bengal tiger and Siberian tiger) are known as intra-specific hybrids. Hybrids between different species within the same genus (such as between lions and tigers) are known as interspecific hybrids or crosses. Hybrids between different genera (such as between sheep and goats) are known as intergeneric hybrids. Natural hybrids will occur in hybrid zones, where two populations of species within the same genera or species living in the same or adjacent areas will interbreed with each other. Some hybrids have been recognized as species, such as the red wolf (though this is controversial). Artificial selection, the deliberate selective breeding of domestic animals, is being used to breed back recently extinct animals in an attempt to achieve an animal breed with a phenotype that resembles that extinct wildtype ancestor. A breeding-back (intraspecific) hybrid may be very similar to the extinct wildtype in appearance, ecological niche and to some extent genetics, but the initial gene pool of that wild type is lost forever with its extinction.
=== Daytime Emmy Awards === Overall 19-time winner: 14-time winner of Daytime Emmy Award for Outstanding Game Show Host, as host of The Price Is Right 4-time winner of Daytime Emmy Award for Outstanding Game Show, as executive producer of The Price Is Right Lifetime Achievement Award, presented at the 1999 Daytime Emmy Awards
Larter next appeared as Zerelda Mimms in the western comedy American Outlaws. Directed by Les Mayfield and co-starring Irish actor Colin Farrell and Scott Caan, the film was poorly received by critics and at the box office making only $13 million. She also starred in Kevin Smith's Jay and Silent Bob Strike Back. In 2001, Larter appeared on the cover of Maxim magazine and performed in the stage play The Vagina Monologues in Manhattan, New York. In Spring 2002, Larter moved from Los Angeles to New York. "I was too young and impressionable to handle the pressures of L.A." Larter later recalled in an interview: "I'm a woman now. I am no longer the little girl who could be easily influenced (back then)." While in New York City, she made herself available for independent film projects and being in theater. Larter's first project in New York City was to reprise her role as Clear Rivers in the sequel to Final Destination entitled Final Destination 2. In an interview with IGN, Larter said, "When New Line asked me to come back, I thought it was great. They showed me the script and let me have some input, and it was really terrific." The film made $90 million worldwide with a mixed critical reception. In 2004, Larter served as an associate producer of and starred in the thriller Three Way.
Some of this pool of 238Pu was used in a multi-mission radioisotope thermoelectric generator (MMRTG) for the 2020 Mars Rover mission and two additional MMRTGs for a notional 2024 NASA mission. 21 kg (46 lb) would remain after that, including approximately 4 kg (8.8 lb) just barely meeting the NASA specification. Since isotope content in the material is lost over time to radioactive decay while in storage, this stock could be brought up to NASA specifications by blending it with a smaller amount of freshly produced 238Pu with a higher content of the isotope, and therefore energy density.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.